Verano Announces Promotion and Appointment of Richard Tarapchak as Chief Financial Officer
CHICAGO, April 14, 2025 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) ('Verano' or the 'Company'), a leading multi-state cannabis company, today announced the promotion and appointment of Richard Tarapchak as the Company's Chief Financial Officer ('CFO'), effective as of April 11, 2025. Tarapchak succeeds Brett Summerer, former Chief Financial Officer, who is departing the Company following his mutually agreed upon resignation.
As CFO and a member of Verano's executive leadership team, Tarapchak, a seasoned financial executive with over three decades of experience, will oversee all financial and accounting operations, strategic financial planning, and information technology for the Company. He joined Verano in July of 2022, and has served as Verano's Executive Vice President, Finance and Corporate Controller and Principal Accounting Officer throughout his tenure with the Company.
Prior to joining Verano, Tarapchak held a variety of accounting and finance leadership positions across a diverse set of industries. His extensive experience includes serving as Vice President, Corporate Controller and Chief Accounting Officer of II-VI Incorporated; Corporate Controller of Reynolds Group Holdings Limited; Chief Financial Officer of National Material L.P.; and several positions at Navistar International Corporation, including, most recently, Senior Vice President and Corporate Controller. Tarapchak earned a business administration degree from Wittenberg University in 1987 and an MBA in finance and accounting from The Ohio State University in 1992. In addition, he is a certified public accountant, and serves as the Chair of the Corporate Controller's Council at the Manufacturers Alliance and as a board member of the Illinois CPA Society.
'I want to thank Brett for his contributions to Verano throughout his tenure with the Company. We have realized many significant milestones over this time period, and I wish him continued success in his future endeavors,' said George Archos, Verano founder and Chief Executive Officer. 'I am pleased with Rich's promotion to Chief Financial Officer given his deep understanding of our core business, and I believe he is extremely well suited to lead Verano's financial operations. Rich has played a pivotal leadership role in the Company's accounting and finance teams, and has demonstrated continued professional growth throughout his tenure at Verano. I have full confidence in his ability to lead our finance team as he builds upon our financial strength, operational excellence, and our deep commitment to our employees, the investment community, and our shareholders. I am confident that with Rich's leadership, we will continue to maintain and enhance Verano's financial strength and stewardship.'
'I am honored to assume the role of Chief Financial Officer and expand my financial leadership within Verano at such an exciting time for the Company,' said Richard Tarapchak, Verano Chief Financial Officer. 'Given Verano's leadership position in the industry, commitment to product innovation, dedication to supporting our customers, and strong history of performance and profitability, I look forward to continuing to collaborate with our dedicated, skilled, and compassionate team to execute our business and financial strategy as we shape the future of the industry.'
About Verano
Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF), one of the U.S. cannabis industry's leading companies based on historical revenue, geographic scope and brand performance, is a vertically integrated, multi-state operator embracing a mission of saying Yes to plant progress and the bold exploration of cannabis. Verano provides a superior cannabis shopping experience in medical and adult use markets under the Zen Leaf™ and MÜV™ dispensary banners, including Cabbage Club™, an innovative annual membership program offering exclusive benefits for cannabis consumers. Verano produces a comprehensive suite of high-quality, regulated cannabis products sold under its diverse portfolio of trusted consumer brands including Verano™, (the) Essence™, MÜV™, Savvy™, BITS™, Encore™, and Avexia™. Verano's active operations span 13 U.S. states, comprised of 15 production facilities with over 1.1 million square feet of cultivation capacity. Learn more at Verano.com.
Media
Verano
Steve Mazeika
VP, Communications
[email protected]
Forward Looking Statements
This press release contains 'forward-looking statements' within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company's beliefs regarding future events, plans, strategies, or objectives, many of which, by their nature, are inherently uncertain and outside of the Company's control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as 'plans', 'expects' or 'does not expect', 'is expected', 'budget', 'future', 'scheduled', 'estimates', 'forecasts', 'projects,' 'intends', 'anticipates' or 'does not anticipate', or 'believes', or variations of such words and phrases, or may contain statements that certain actions, events or results 'may', 'could', 'would', 'might' or 'will be taken', 'will continue', 'will occur' or 'will be achieved'. Forward-looking statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking statements herein, including, without limitation, the risk factors described in the Company's annual report on Form 10-K for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission at www.sec.gov. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information or forward-looking statements that are contained or referenced herein, except as may be required in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice regarding forward-looking information and statements.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Larkspur Biosciences Announces Discovery of LRK-4189, a First-in-Class Degrader of the Lipid Kinase PIP4K2C, for the Treatment of Microsatellite Stable (MSS) Colorectal Cancer at the ACS Fall 2025 Meeting
First-in-human, Phase 1 Study of LRK-4189 to Begin in the Fourth Quarter CAMBRIDGE, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Larkspur Biosciences, a company pioneering a new wave in cancer therapy that destroys tumors by targeting cancer cell fitness, today announced the discovery of LRK-4189, a first-in-class degrader of the lipid kinase PIP4K2C for the treatment of microsatellite stable (MSS) colorectal cancer (CRC) and other solid tumors. The announcement was made at a presentation Larkspur was invited to give at the prestigious MEDI First Time Disclosures: Breakthroughs on New Medicines session at ACS Fall 2025, a meeting of the American Chemical Society in Washington, DC. Cancer cells maintain their fitness by developing survival adaptations that foster escape from intrinsic and extrinsic mechanisms of cell death in conditions of stress. Phosphatidylinositol 5-phosphate 4-kinase, type II, gamma (PIP4K2C) is a lipid kinase associated with poor outcomes in a range of cancers including CRC and breast cancers. PIP4K2C is co-opted by cancer cells to increase their fitness by evading immune surveillance and adapting to stress. 'Genetic studies have long highlighted PIP4K2C as a key player in cancer stress adaptation, but its extremely low kinase activity made it resistant to conventional inhibition approaches,' said Catherine Sabatos-Peyton, PhD, CEO of Larkspur Biosciences. 'With our novel degrader, LRK-4189, we've finally unlocked this critical pathway. By reducing cancer cell fitness, triggering intrinsic apoptosis, and engaging the immune system to clear residual tumor cells, LRK-4189 has the potential to overcome the limitations of earlier therapies. We're excited to advance this promising therapy to the clinic later this year.' According to the American Cancer Society, in the United States, approximately 150,000 cases of CRC are diagnosed annually, with MSS CRC accounting for about 85% of all CRC cases. About LRK-4189 LRK-4189 is an orally bioavailable, selective degrader of PIP4K2C with subnanomolar potency in primary human cells. LRK-4189-mediated degradation of PIP4K2C leads to intrinsic cancer cell death and activates interferon signaling, triggering multiple killing mechanisms in difficult-to-treat MSS CRC cells. In vivo, LRK-4189 demonstrates dose dependent PKPD with single agent efficacy in multiple models of CRC and synergy with first-line standard of care chemotherapy. In primary human CRC patient-derived spheroids, 50% of patient samples respond to LRK-4189 with a preferential response in MSS CRC, which compares favorably to benchmark cetuximab in the same platform (35%). Cetuximab may be either a first- or second-line treatment in people with RAS wild type CRC. LRK-4189 has completed IND-enabling studies and expects to initiate a Phase 1 clinical trial in Q4 2025. About Larkspur Biosciences Larkspur Biosciences is pioneering a new wave in cancer therapy that destroys tumors by targeting cancer cell fitness. Larkspur develops therapies that decrease cancer cell fitness and sensitizes the cells to intrinsic and immune-driven mechanisms of killing. The company is advancing first-in-class programs that target the adaptations cancer cells use to proliferate, invade tissue, and escape the immune system. LarkX, the company's proprietary bioinformatics platform, couples machine learning with tumor genetics to discover cancer cell fitness pathways that originate in the tumor and enrich clinical strategies for potential responders to its therapies across multiple types of cancer. Larkspur's founders include Lewis C. Cantley, PhD, professor of medicine at Dana-Farber Cancer Institute, professor of cell biology at Harvard Medical School; Vijay K. Kuchroo, DVM, PhD, professor of neurology at Harvard Medical School, senior scientist at Brigham and Women's Hospital; and Nathanael Gray, PhD, professor of chemical and systems biology at Stanford University. Visit us at and follow us on LinkedIn and X. Media Contact:Dan BoyleScientPRdan@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Hepsiburada Submits Amendment to 6-K
ISTANBUL, Aug. 20, 2025 (GLOBE NEWSWIRE) -- On August 15, 2025, D-MARKET Elektronik Hizmetler ve Ticaret Anonim Şirketi (the 'Company') furnished to the Securities and Exchange Commission a Form 6-K (the 'Original Form 6-K') containing certain exhibits relating to the Company's Annual General Assembly Meeting of Shareholders for, and with respect to, the financial year 2024, to be held on September 15, 2025. This Amendment No. 1 to the Original Form 6-K amends the Original Form 6-K solely for the purpose of amending and restating Exhibit 99.4 (Board of Directors' Annual Report for 2024) in its entirety, due to an inadvertent clerical error contained in the version included in the Original Form 6-K. Except as described above, the Original Form 6-K remains unchanged. About Hepsiburada Hepsiburada is a leading e-commerce technology platform in Türkiye, operating through a hybrid model that combines first-party direct sales (1P) and a third-party marketplace (3P) with approximately 100 thousand its vision of leading the digitalization of commerce, Hepsiburada serves as a reliable, innovative and purpose-driven companion in consumers' daily lives. Hepsiburada's e-commerce platform offers a broad ecosystem of capabilities for merchants and consumers including last-mile delivery, fulfilment services, advertising solutions, cross-border sales, payment services and affordability solutions. Hepsiburada's integrated fintech platform, Hepsipay, provides secure payment solutions, including digital wallets, general-purpose loans, buy now pay later (BNPL) and one-click checkout, enhancing shopping convenience for consumers across online and offline while driving higher sales conversions for its founding in 2000, Hepsiburada has been purpose-driven, leveraging its digital capabilities to empower women in the Turkish economy. In 2017, Hepsiburada launched the 'Technology Empowerment for Women Entrepreneurs' program, which has supported approximately 65 thousand female entrepreneurs across Türkiye in reaching millions of customers. Investor Relations Contactir@ Media Contactcorporatecommunications@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Onco360 adds Modeyso™ (dordaviprone) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider
LOUISVILLE, Ky., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation's leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Jazz Pharmaceuticals for Modeyso™ (dordaviprone). It is indicated for the treatment of adult and pediatric patients one year of age and older with diffuse midline glioma harboring an H3 K27M-mutation with progressive disease following prior therapy.1 This indication was approved based on five open-label, non-randomized clinical trials conducted in the U.S. (ONC006 [NCT02525692], ONC013 [NCT03295396], ONC014 [NCT03416530], ONC016 [NCT05392374], and ONC018 [NCT03134131]).1 'Onco360 is grateful for the opportunity to add Modeyso™ to our expansive portfolio of cancer and rare disease therapies as the first and only FDA-approved treatment for pediatric and adult patients with diffuse midline glioma,' said Benito Fernandez. 'We are proud and humbled to be part of this innovative treatment in support of patients, caregivers and families impacted by this devastating disease.' Dordaviprone is a protease activator of the mitochondrial caseinolytic protease P (ClpP) and inhibits dopamine D2 receptor (DRD2). In vitro, dordaviprone activates the integrated stress response, induces apoptosis, and alters mitochondrial metabolism, leading to restored histone H3 K27 trimethylation in H3 K27M-mutant diffuse glioma.1 The efficacy of Modeyso was evaluated in an integrated efficacy population of 50 adult and pediatric patients with recurrent H3 K27M-mutant diffuse midline glioma enrolled across five open-label, non-randomized clinical trials.1 The primary outcome was overall response rate (ORR) of 22% (95% CI: 12,36). The trial also demonstrated a duration of response of 10.3 months (95% CI: 7.3, 15.2) with 73% maintaining their response for at least six months and 27% for at least 12 months.1 Dordaviprone demonstrated manageable safety and tolerability adverse events. The most common adverse reactions (≥20 %; all causality) experienced with dordaviprone were fatigue, headache, nausea, vomiting, and musculoskeletal pain.1 Please see the full Prescribing Information for Modeyso. About Onco360 Oncology Pharmacy:Onco360 is the nation's largest independent Oncology Pharmacy and clinical support services company. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit Media Contact: Benito Fernandez, Chief Commercial References:1Modeyso™ (Dordaviprone) [Package Insert]. Palo Alto, CA. Jazz Pharmaceuticals. in to access your portfolio
